4 reports

  • TARGET COMPANY INFORMATION COMPANY NAME
  • DEAL INFORMATION DEAL STATUS COMPLETED DATE DEAL FINANCIALS

Rebellious genes are the ones that are working when/ where they should not e. g. in cancers, inflammatory conditions, Alzheimer' s and autoimmune diseases.

  • Cancer
  • Therapy
  • United Kingdom
  • ValiRx Plc
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • VALIRX ENTERS INTO AGREEMENT WITH GERMAN CANCER RESEARCH CENTER FOR VAL-101
  • FINANCIAL ADVISOR

Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer.The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing of specific genes...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United Kingdom
  • ValiRx Plc